Return to homepagePandemic Pact

Moderna - COVID-19

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $1,000,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    .

  • Research Location

    United States of America

  • Lead Research Institution

    Moderna

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    Innovation

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

OSLO, NORWAY. Jan 23, 2020 - CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the initiation of three programmes to develop vaccines against the novel coronavirus, nCoV-2019. The programmes will leverage rapid response platforms already supported by CEPI as well as a new partnership. The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible. The nCoV-2019 vaccine development efforts will build on existing partnerships with Inovio (Nasdaq: INO) and The University of Queensland (located in Brisbane, Australia). In addition, CEPI today announces a new partnership with Moderna, Inc., (Nasdaq: MRNA) and the U.S. National Institute of Allergy and Infectious Diseases. All of these are pioneering technologies designed to speed up the development of vaccines against emerging threats such as nCoV-2019.